. Agoniste-dopaminergique-polymorphe, agoniste sérotoninergique et adrénergique, molécule neuroprotectrice, l'apomorphine se révèle donc d'un grand

A. Subramony and J. , Apomorphine in Dopaminergic Therapy, Molecular Pharmaceutics, vol.3, issue.4, pp.380-385, 2006.
DOI : 10.1021/mp060012c

A. Antonini, Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson???s Disease, Journal of Movement Disorders, vol.2, issue.1, pp.4-9, 2009.
DOI : 10.14802/jmd.09002

A. Argiolas and H. Hedlund, The pharmacology and clinical pharmacokinetics of apomorphine SL, BJU International, vol.24, pp.18-21, 2001.
DOI : 10.1046/j.1464-4096.2001.00124.x

F. Blandini and M. Armentero, Dopamine receptor agonists for Parkinson's disease, Expert Opinion on Investigational Drugs, vol.17, issue.2, pp.387-410, 2014.
DOI : 10.1124/jpet.102.039883

A. Bowron, Practical considerations in the use of apomorphine injectable, Neurology, vol.62, issue.Issue 6, Supplement 4, pp.32-36, 2004.
DOI : 10.1212/WNL.62.6_suppl_4.S32

A. Boyle and W. Ondo, Role of Apomorphine in the Treatment of Parkinson???s Disease, CNS Drugs, vol.24, issue.8, pp.83-89, 2015.
DOI : 10.1007/s40263-014-0221-z

J. Brotchie, Nondopaminergic mechanisms in levodopa-induced dyskinesia, Movement Disorders, vol.5, issue.8, pp.919-931, 2005.
DOI : 10.1002/mds.20612

E. Broussolle, L. Cinotti, P. Pollak, P. Landais, L. Bars et al., Relief of akinesia by apomorphine and cerebral metabolic changes in parkinson's disease, Movement Disorders, vol.7, issue.suppl 1, pp.459-462, 1993.
DOI : 10.1002/mds.870080407

K. Chaudhuri, A. Rizos, and K. Sethi, Motor and nonmotor complications in Parkinson???s disease: an argument for continuous drug delivery?, Journal of Neural Transmission, vol.74, issue.Suppl 1, pp.1305-1320, 2013.
DOI : 10.1007/s00702-013-0981-5

J. Chen and C. Obering, A review of intermittent subcutaneous apomorphineinjections for the rescue management of motor fluctuations associated with advanced Parkinson's disease, Clinical Therapeutics, vol.27, issue.11, pp.1710-1724, 2005.
DOI : 10.1016/j.clinthera.2005.11.016

L. Collins, A. Toulouse, T. Connor, and Y. Nolan, Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease, Neuropharmacology, vol.62, issue.7, pp.2154-2168, 2012.
DOI : 10.1016/j.neuropharm.2012.01.028

C. Colosimo, M. Merello, and A. Albanese, Clinical Usefulness of Apomorphine in Movement Disorders, Clinical Neuropharmacology, vol.17, issue.3, pp.243-259, 1994.
DOI : 10.1097/00002826-199406000-00004

G. Conti, F. Blandini, C. Tassorello, F. Giubilei, F. Foranai et al., Intrastriatal injection of D1 or D2 dopamine agonists affects glucose utilization in both the direct and indirect pathways of the rat basal ganglia, Neuroscience Letters, vol.309, issue.3, pp.161-164, 2001.
DOI : 10.1016/S0304-3940(01)02068-7

D. Deleu, Y. Hanssens, and M. Northway, Subcutaneous Apomorphine, Drugs & Aging, vol.58, issue.11, pp.687-709, 2004.
DOI : 10.2165/00002512-200421110-00001

L. Dépatie and S. Lal, Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?, J Psychiatry Neurosci, vol.26, issue.3, pp.203-223, 2001.

S. Drapier and M. Vérin, L???apomorphine en perfusion sous-cutan??e continue dans le traitement de la maladie de Parkinson, Revue Neurologique, vol.162, issue.10, pp.10-1019, 2006.
DOI : 10.1016/S0035-3787(06)75115-3

C. Ellis, G. Lemmens, J. Parkes, R. Abbott, I. Pye et al., Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment, Parkinsonism & Related Disorders, vol.3, issue.2, pp.103-107, 1997.
DOI : 10.1016/S1353-8020(97)00009-6

S. Factor, Literature review: Intermittent subcutaneous apomorphine therapy in Parkinson's disease, Neurology, vol.62, issue.Issue 6, Supplement 4, pp.12-17, 2004.
DOI : 10.1212/WNL.62.6_suppl_4.S12

S. Gancher, J. Nutt, and W. Woodward, Absorption of apomorphine by various routes in parkinsonism, Movement Disorders, vol.1, issue.3, pp.212-216, 1991.
DOI : 10.1002/mds.870060304

J. Garrido, C. Delerue-matos, F. Borges, T. Macedo, and A. Oliveira-brett, New insights into the oxidation pathways of apomorphine, Journal of the Chemical Society, Perkin Transactions 2, issue.10, pp.1713-1717, 2002.
DOI : 10.1039/b204605a

M. Gassen, Y. Glinka, B. Pinchasi, and M. Youdim, Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction, European Journal of Pharmacology, vol.308, issue.2, pp.219-225, 1996.
DOI : 10.1016/0014-2999(96)00291-9

I. Haq, P. Lewitt, and H. Fernandez, Apomorphine therapy in Parkinson's disease: a review, Expert Opinion on Pharmacotherapy, vol.62, issue.16, pp.2799-2809, 2007.
DOI : 10.1212/01.wnl.0000215250.82576.87

H. Hara, M. Ohta, and T. Adachi, Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway, Journal of Neuroscience Research, vol.93, issue.4, pp.860-866, 2006.
DOI : 10.1002/jnr.20974

N. Hattori and M. Nomoto, 6500-004 Study Group. Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson's Disease. Parkinsonism and related disorders, pp.819-823, 2014.

T. Henriksen, Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians, Neurodegenerative Disease Management, vol.4, issue.3, pp.271-282, 2014.
DOI : 10.2217/nmt.14.17

E. Himeno, Y. Ohyagi, L. Ma, N. Nakamura, K. Miyoshi et al., Apomorphine treatment in Alzheimer mice promoting amyloid-?? degradation, Annals of Neurology, vol.108, issue.2, pp.248-256, 2011.
DOI : 10.1002/ana.22319

A. Hughes, S. Bishop, B. Kleedorfer, N. Turjanski, W. Fernandez et al., Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years, Movement Disorders, vol.4, issue.2, pp.165-170, 1993.
DOI : 10.1002/mds.870080208

P. Kempster, J. Frankel, G. Stern, and A. Lees, Comparison of motor response to apomorphine and levodopa in Parkinson's disease., Journal of Neurology, Neurosurgery & Psychiatry, vol.53, issue.11, pp.1004-1007, 1990.
DOI : 10.1136/jnnp.53.11.1004

W. Koller and M. Stacy, Other formulations and future considerations for apomorphine for subcutaneous injection therapy, Neurology, vol.62, issue.Issue 6, Supplement 4, pp.22-26, 2004.
DOI : 10.1212/WNL.62.6_suppl_4.S22

A. Lees, Dopamine agonists in Parkinson's disease: a look at apomorphine, Fundamental & Clinical Pharmacology, vol.ii, issue.3-4, pp.121-128, 1993.
DOI : 10.1111/j.1472-8206.1993.tb00226.x

P. Lewitt, Subcutaneously administered apomorphine: Pharmacokinetics and metabolism, Neurology, vol.62, issue.Issue 6, Supplement 4, pp.8-11, 2004.
DOI : 10.1212/WNL.62.6_suppl_4.S8

A. Lozano, A. Lang, R. Levy, W. Hutchison, and J. Dostrovsky, Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine, Ann Neurol, vol.47, pp.141-146, 2000.

A. Manson, H. Hanagasi, K. Turner, P. Patsalos, P. Carey et al., Intravenous apomorphine therapy in Parkinson's disease: Clinical and pharmacokinetic observations, Brain, vol.124, issue.2, pp.331-340, 2001.
DOI : 10.1093/brain/124.2.331

R. Menon and M. Stacy, Apomorphine in the treatment of Parkinson's disease, Expert Opinion on Pharmacotherapy, vol.16, issue.12, pp.1941-1950, 2007.
DOI : 10.1002/mds.870130505

L. Metman, E. Locatelli, D. Bravi, M. Mouradian, and T. Chase, Apomorphine responses in parkinson's disease and the pathogenesis of motor complications, Neurology, vol.48, issue.2, pp.369-372, 1997.
DOI : 10.1212/WNL.48.2.369

F. Montorsi, D. Perani, D. Anchisi, A. Salonia, P. Scifo et al., Apomorphine-induced brain modulation during sexual stimulation: a new look at central phenomena related to erectile dysfunction, International Journal of Impotence Research, vol.15, issue.3, pp.203-209, 2003.
DOI : 10.1038/sj.ijir.3900999

D. Muguet, E. Broussolle, and G. Chazot, Apomorphine in patients with Parkinson's disease, Biomedicine & Pharmacotherapy, vol.49, issue.4, pp.197-209, 1995.
DOI : 10.1016/0753-3322(96)82620-5

E. Nicolle, P. Pollak, F. Serre-debeauvais, P. Richard, C. Gervason et al., Pharmacokinetics of apomorphine in parkinsonian patients, Fundamental & Clinical Pharmacology, vol.i, issue.5, pp.245-252, 1993.
DOI : 10.1111/j.1472-8206.1993.tb00238.x

D. Nyholm, The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease, Parkinsonism & Related Disorders, vol.13, pp.13-17, 2007.
DOI : 10.1016/j.parkreldis.2007.06.005

K. Pietz, P. Hagell, and P. Odin, Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up, Journal of Neurology, Neurosurgery & Psychiatry, vol.65, issue.5, pp.709-716, 1998.
DOI : 10.1136/jnnp.65.5.709

R. Pfeiffer, L. Gutmann, H. Jr, . Kl, P. Bottini et al., Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease, Parkinsonism & Related Disorders, vol.13, issue.2, pp.93-100, 2007.
DOI : 10.1016/j.parkreldis.2006.06.012

W. Poewe and G. Wenning, Apomorphine: An underutilized therapy for Parkinson's disease, Movement Disorders, vol.51, issue.5, pp.789-794, 2000.
DOI : 10.1002/1531-8257(200009)15:5<789::AID-MDS1005>3.0.CO;2-H

M. Rambour, C. Moreau, J. Salleron, D. Devos, A. Kreisler et al., Le traitement par apomorphine en perfusion continue sous-cutan??e dans la maladie de Parkinson??: analyse r??trospective d???une s??rie de 81??patients, Revue Neurologique, vol.170, issue.3, pp.205-215, 2014.
DOI : 10.1016/j.neurol.2013.10.012

S. Ribaric, The Pharmacological Properties and Therapeutic Use of Apomorphine, Molecules, vol.17, issue.12, pp.5289-5309, 2012.
DOI : 10.3390/molecules17055289

E. Ruzicka, J. Roth, N. Spackova, P. Mecir, and R. Jech, Apomorphine induced cognitive changes in Parkinson's disease., Journal of Neurology, Neurosurgery & Psychiatry, vol.57, issue.8, pp.998-1001, 1994.
DOI : 10.1136/jnnp.57.8.998

E. Sam, S. Sarre, Y. Michotte, and N. Verbeke, Distribution of apomorphine enantiomers in plasma, brain tissue and striatal extracellular fluid, European Journal of Pharmacology, vol.329, issue.1, pp.9-15, 1997.
DOI : 10.1016/S0014-2999(97)10082-6

P. Seeman, V. Tol, and M. , Dopamine receptor pharmacology, Trends in Pharmacological Sciences, vol.15, issue.7, pp.264-70, 1994.
DOI : 10.1016/0165-6147(94)90323-9

M. Stacy and D. Silver, Apomorphine for the acute treatment of ???off??? episodes in Parkinson's disease, Parkinsonism & Related Disorders, vol.14, issue.2, pp.85-92, 2008.
DOI : 10.1016/j.parkreldis.2007.07.016

M. Stacy and . Apomorphine, Apomorphine: North American clinical experience, Neurology, vol.62, issue.Issue 6, Supplement 4, pp.18-21, 2004.
DOI : 10.1212/WNL.62.6_suppl_4.S18

M. Steiger, N. Quinn, and C. Marsden, The clinical use of apomorphine in Parkinson's disease, J Neurol, vol.239, pp.389-393, 1992.

F. Stocchi and C. Olanow, Continuous dopaminergic stimulation in early and advanced Parkinson's disease, Neurology, vol.62, issue.Issue 1, Supplement 1, pp.56-63, 2004.
DOI : 10.1212/WNL.62.1_suppl_1.S56

O. Sujith and C. Lane, Review: Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease, Therapeutic Advances in Neurological Disorders, vol.68, issue.1, pp.105-113, 2009.
DOI : 10.1177/1756285608101378

E. Tolosa, M. Marti, F. Valldeoriola, and J. Molinuevo, History of levodopa and dopamine agonists in Parkinson's disease treatment, Neurology, vol.50, issue.Issue 6, Supplement 6, pp.2-10, 1998.
DOI : 10.1212/WNL.50.6_Suppl_6.S2

C. Trenkwalder, K. Chaudhuri, G. Ruiz, P. Lewitt, P. Katzenschlager et al., on behalf of an Expert Consensus Group for the Use of Apomorphine in Parkinson's Disease, Expert consensus group report on the use of apomorphine in the treatment of Parkinson's disease-Clinical practice recommendations, pp.1023-1030, 2015.

H. Tyne, J. Parsons, A. Sinnott, S. Fox, N. Fletcher et al., A 10 year retrospective audit of long-term apomorphine use in Parkinson?s disease, Journal of Neurology, vol.48, issue.11, pp.1370-1374, 2004.
DOI : 10.1007/s00415-004-0547-4

F. Vaglini, C. Pardini, C. Viaggi, A. Caramelli, and G. Corsini, Apomorphine offers new insight into dopaminergic neuron vulnerability in mesencephalic cultures, Neuropharmacology, vol.55, issue.5, pp.737-742, 2008.
DOI : 10.1016/j.neuropharm.2008.06.041

R. Van-der-geest, P. Kruger, J. Gubbens-stibbe, T. Van-laar, H. Bodde et al., Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfat conjugates in plasma and urine of patients with Parkinson's disease, Journal of Chromatography B, pp.702-131, 1997.

T. Van-laar, B. Van-hilten, C. Neef, A. Rutgers, S. Pavel et al., The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: A histologic study, Movement Disorders, vol.1, issue.1, pp.52-55, 1998.
DOI : 10.1002/mds.870130113

J. Van-hooft, Agonist and antagonist effects of apomorphine enantiomers on 5-HT3 receptors, Neuropharmacology, vol.37, issue.2, pp.259-264, 1998.
DOI : 10.1016/S0028-3908(98)00044-6

E. Walter and P. Odin, Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson???s disease in the UK and Germany, Journal of Medical Economics, vol.18, issue.2, pp.155-65, 2015.
DOI : 10.3111/13696998.2014.979937

K. Wenzel, C. Homann, G. Fabbrini, and C. Colosimo, The role of subcutaneous infusion of apomorphine in Parkinson???s disease, Expert Review of Neurotherapeutics, vol.14, issue.7, pp.833-843, 2014.
DOI : 10.1586/14737175.2014.928202

F. Zagnoli, F. Rouhart, and . Maladie-de-parkinson, Doin, Collection conduites, France. 209 pages, p.2, 2006.

J. Zijlmans, B. Debilly, O. Rascol, A. Lees, and F. Durif, Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study, Movement Disorders, vol.8, issue.9, pp.1006-1011, 2004.
DOI : 10.1002/mds.20188